Mekinist

Summary

Name(s) Target Manufacturer Status
Mekinist, trametinib MAP2K1, MAP2K2 GlaxoSmithKline FDA approved for: Melanoma, BRAF V600E mutated, Melanoma, BRAF V600K mutated

Clinical Trials

Trial Drug Status Phase
A Study of the BRAF Inhibitor Dabrafenib in Combination With the MEK Inhibitor Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection. [NCT01682083] Tafinlar, Mekinist Recruiting Phase 3
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma [NCT01597908] Tafinlar, Zelboraf, Mekinist Recruiting Phase 3
Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery [NCT01701037] Tafinlar, Mekinist Recruiting Phase 2
LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations [NCT01726738] Tafinlar, Mekinist Recruiting Phase 2
Tumor Gene Variations and Treatment Options for Advanced Solid Tumors [NCT01827384] Temodar, Afinitor, Carboplatin, Mekinist, veliparib, MK-1775 Not yet recruiting Phase 2
GSK2118436 and GSK1120212 [NCT01619774] Tafinlar, Mekinist Recruiting Phase 2
GSK1120212 Rollover Study [NCT01376310] Mekinist, Taxotere, Tarceva, Alimta, Carboplatin, Abraxane, Gemzar, Afinitor Recruiting Phase 2
Trametinib With GSK2141795 in BRAF Wild-type Melanoma [NCT01941927] Mekinist, GSK2141795 Recruiting Phase 2
Dabrafenib/Trametinib/Navitoclax In Braf Mutant Melanoma [NCT01970956] ABT-263, Tafinlar, Mekinist Not yet recruiting Phase 1/Phase 2
A Dose Escalation Study to Assess Safety of GSK2256098 (FAK Inhibitor) in Combination With Trametinib (MEK Inhibitor) in Subjects With Advanced Solid Tumors [NCT01938443] Gsk2256098, Mekinist Not yet recruiting Phase 1
Safety, PK of AKT and MEK Combination [NCT01138085] Mekinist, GSK2141795 Recruiting Phase 1
A Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trametinib, in Subjects With Solid Tumor Malignancies [NCT01725100] Mekinist Recruiting Phase 1
Study Determining the Safety and Tolerability of Combination Therapy With Pazopanib and GSK1120212 in Advanced Solid Tumors Enriched With Patients With Advanced Differentiated Thyroid Cancer [NCT01438554] Votrient, Mekinist Recruiting Phase 1
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212 [NCT01658553] Mekinist Recruiting Phase 1
Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma [NCT01767454] Tafinlar, Mekinist, Yervoy Recruiting Phase 1
Ipilimumab With or Without Dabrafenib, and/or Trametinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed By Surgery [NCT01940809] Yervoy, Tafinlar, Mekinist Recruiting Phase 1
A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors [NCT01231594] Tafinlar, Mekinist Recruiting Phase 1

Suggested Reading / Relevant Literature

#